HUB Investment Partners LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

HUB Investment Partners LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 4.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,676 shares of the biopharmaceutical company’s stock after selling 3,047 shares during the period. HUB Investment Partners LLC’s holdings in Pfizer were worth $1,875,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Northwest & Ethical Investments L.P. boosted its holdings in shares of Pfizer by 0.6% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 265,072 shares of the biopharmaceutical company’s stock valued at $7,032,000 after acquiring an additional 1,541 shares during the last quarter. Berkeley Capital Partners LLC boosted its holdings in shares of Pfizer by 2.3% in the 4th quarter. Berkeley Capital Partners LLC now owns 69,190 shares of the biopharmaceutical company’s stock valued at $1,836,000 after acquiring an additional 1,531 shares during the last quarter. Fiduciary Group LLC boosted its holdings in Pfizer by 36.5% during the fourth quarter. Fiduciary Group LLC now owns 117,669 shares of the biopharmaceutical company’s stock worth $3,122,000 after buying an additional 31,479 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Pfizer by 93.3% during the fourth quarter. Teacher Retirement System of Texas now owns 1,969,261 shares of the biopharmaceutical company’s stock worth $52,244,000 after buying an additional 950,358 shares in the last quarter. Finally, Royal London Asset Management Ltd. boosted its holdings in Pfizer by 2.8% during the fourth quarter. Royal London Asset Management Ltd. now owns 2,461,076 shares of the biopharmaceutical company’s stock worth $65,292,000 after buying an additional 67,788 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.17 on Friday. The firm has a 50-day simple moving average of $26.18 and a 200-day simple moving average of $27.07. The stock has a market capitalization of $148.29 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the business earned $0.10 earnings per share. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.